Published in Blood Weekly, July 27th, 2000
In the July 14 issue of the Lancet, The Rapamune U.S. Study Group reported the findings of their study that compared two drug combinations to test their effectiveness in reducing the rate of renal graft (allograft) rejections.
Sirolimus has provided potent immunosuppression in laboratory experiments and powerful protection against rejection episodes when combined with the drug cyclosporin in human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.